News
-
-
PRESS RELEASE
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
Bausch Health Companies Inc. presents positive data from Amiselimod clinical trials for ulcerative colitis treatment at global healthcare conferences. Rifaximin monotherapy data also showed promise for hepatic encephalopathy recurrence prevention -
-
PRESS RELEASE
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
Bausch Health Canada expands UCERIS availability in Canadian public drug plans for ulcerative colitis treatment. UCERIS foam offers better tolerability and application compared to enema -
-
PRESS RELEASE
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
Bausch Health & Salix Pharmaceuticals to present Phase 2 trial data on Amiselimod for ulcerative colitis treatment at DDW 2024. Positive results announced in 2023 -
-
-
-
PRESS RELEASE
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
Bausch Health and Salix Pharmaceuticals provide updates on litigation with Norwich Pharmaceuticals and potential generic version of XIFAXAN. Bausch Health to enforce intellectual property rights. Details on FDA approval process and patent infringement lawsuit
-
Allied Universal Event Services Professional Winner of Golden State Warriors’ Champion Spotlight Annual Starting 5
-
Viking Capital Announces Closing of Latest 252 Unit Acquisition in Austin - San Antonio Corridor
-
Assays Confirm High-Grade Tarcoola Open Pit Extensions
-
Seismic Survey Reveals Tarcoola Goldfield Architecture
-
OTCQB Trading Secured with DTCC Registration Approval
-
Turkiye Garanti Bankasi A.S.: Prospectus – Summary
-
Turkiye Garanti Bankasi A.S.: Prospectus – Capital Markets Instrument Note
-
EQS-Adhoc: United Internet AG: Non-scheduled, non-cash impairment on Tele Columbus investment
-
Shelly Group: Successful placement of shares with participation of BIT Capital for targeted increase in free float
-
Extraordinary General Meeting of 12 June 2024 - All proposals of the Board of Directors were confirmed by the General Meeting
-
Monthly disclosure of the total number of shares and voting rights - 31/05/2024
-
Combined General Meeting, June 13, 2024
-
Europorte and Kerlink revolutionize freight by launching Track Value, the first logistics application using Kinéis IoT space connectivity
-
AXA: Information relating to the number of voting rights and shares making up the share capital on 31/05/2024
-
Declaration of voting rights at the end of May 2024